Inhibitory role of cholinergic system mediated via α7 nicotinic acetylcholine receptor in LPS-induced neuro-inflammation

Innate Immunity

Volumn 16, Issue 1, 2010, Pages 3-13

  Tyagi, Ethika ^a   Agrawal, Rahul ^a   Nath, Chandishwar ^a   Shukla, Rakesh ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

422 nicotinic acetylcholine receptor; 7 Nicotinic acetylcholine receptor; Lipopolysaccharide; Nicotine; Oxotremorine; Pro inflammatory cytokines

Indexed keywords

BUNGAROTOXIN RECEPTOR; CYTOKINE; DIHYDRO BETA ERYTHROIDINE; LIPOPOLYSACCHARIDE; MESSENGER RNA; METHYLLYCACONITINE; MUSCARINIC RECEPTOR; NICOTINE; OXOTREMORINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; HIPPOCAMPUS; HYPOTHALAMUS; INHIBITION KINETICS; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ACONITINE; ANIMALS; BRAIN; CYTOKINES; DIHYDRO-BETA-ERYTHROIDINE; ENCEPHALITIS; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; NEUROIMMUNOMODULATION; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; OXOTREMORINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

RATTUS;

EID: 75449116560     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909104680     Document Type: Article

References (31)

1. Nathan C. Points of control in inflammation. Nature 2002 ; 420: 846-852.
2. Oken RJ Towards a unifying hypothesis of neurodegenerative diseases and a concomitant rational strategy for their prophylaxis and therapy. Med Hypotheses 1995 ; 45: 341-342.
3. Araujo DM, Lapchak P., Collier B., Quirion R. Localization of IL-2 immunoreactivity and IL-2 receptors in the rat brain: interaction with the cholinergic system. Brain Res 1989 ; 498: 257-266.
4. Tyagi E., Agrawal R., Nath C., Shukla R. Influence of LPS-induced neuroinflammation on acetylcholinesterase activity in rat brain. J Neuroimmunol 2008 ; 205: 51-56.
5. Tyagi E., Agrawal R., Nath C., Shukla R. Effect of anti dementia drugs on LPS induced neuroinflammation in mice. Life Sci 2007 ; 80: 1977-1983.
6. Quan N., Sundar SK, Weiss JM Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. J Neuroimmunol 1994 ; 49: 125-134.
7. Nizri E., Amitay YH, Sicsic C., Lavon I., Brenner T. Antiinflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006 ; 50: 540-547.
8. Pavlov VA, Wang H., Czura CJ, Friedman SG, Tracey KJ The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med 2003 ; 9: 125-134.
9. Borovikova LV, Ivanova S., Zhang M. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000 ; 405: 458-462.
10. Rinne JO, Kaasinen V., J̈Currency signrvenp̈Currency sign̈Currency sign T. et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimerĝs disease. J Neurol Neurosurg Psychiatry 2003 ; 74: 113-115.
11. Reale M., Iarlori C., Gambi F. et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patient modulates the expression and production of the proinflammatory and anti-inflammatory cytokines. J Neuroimmunol 2004 ; 148: 162-171.
12. Wang H., Yu M., Ochani M. et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003 ; 421: 384-388.
13. Glowinski J., Iversen LL Regional studies of catecholamines in the rat brain-I. The disposition of [3H]-norepinephrine, [3H]dopamine and [3H]-dopa in various regions of the brain. J Neurochem 1966 ; 13: 655-670.
14. Deak T., Bellamy C., DĝAgostino LG Exposure to forced swim stress does not alter central production of IL-1. Brain Res 2003 ; 972: 53-63.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ Protein measurement with the Folin phenol reagent. J Biol Chem 1951 ; 193: 265-275.
16. Tracey KJ The inflammatory reflex. Nature 2002 ; 420: 853-859.
17. Shytle RD, Mori T., Townsend K. et al. Cholinergic modulation of microglia activation by α7 nicotinic receptors. J Neurochem 2004 ; 89: 337-343.
18. Kawashima K., Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci 2003 ; 72: 2101-2109.
19. Pavlov VA, Ochani M., Gallowitsch-Puerta M. et al. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 2006 ; 103: 5219-5223.
20. Simone RD, Ajmone-Cat MA, Carnevale D., Minghetti L. Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflamm 2005 ; 2: 1-10.
21. Mihailescu S., Drucker-Colin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 2000 ; 31: 131-144.
22. Kihara T., Shimohama S., Sawada H. et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997 ; 42: 159-163.
23. Zamani MR, Allen YS, Owen GP, Gray JA Nicotine modulates the neurotoxic effect of beta-amyloid protein (25-35) in hippocampal cultures. Neuroreport 1997 ; 8: 513-517.
24. Hellstrom-Lindahl E., Court J., Keverne J. et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 2004 ; 19: 2703-2710.
25. Nordberg A., Hellstrom-Lindahl E., Lee M. et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimerĝs disease (APPsw). J Neurochem 2002 ; 81: 655-658.
26. Shimohama S., Taniguchi T., Fujiwara M., Kameyama M. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 1986 ; 46: 288-293.
27. Perry EK, Morris CM, Court JA et al. Alteration in nicotinic binding sites in Parkinsonĝs disease, Lewy body dementia and Alzheimerĝs disease: possible index of early neuropathology. Neuroscience 1994 ; 64: 385-395.
28. Buisson B., Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 2002 ; 23: 130-136.
29. Takatori YT, Kume T., Sugimoto M., Katsuki H., Sugimoto H., Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimerĝs disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006 ; 51: 474-486.
30. Hellstrom-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res 1999 ; 66: 94-103.
31. Wevers A., Schroder H. Nicotinic acetylcholine receptors in Alzheimerĝs disease. J Alzheimers Dis 1999 ; 1: 207-219.